Shanghai Bao Pharmaceuticals' (HKG:2659) investigational new drug application for a clinical trial of BJ045 for Injection was approved by China's National Medical Products Administration.
The drug was developed for the potential treatment of moderate-to-severe autoimmune diseases in combination with IgG-degrading enzymes, a Tuesday bourse filing showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments